New drug combo tested for Tough-to-Treat blood cancer
NCT ID NCT04405167
Summary
This early-stage study tested a drug called tasquinimod, both by itself and combined with standard myeloma medications, in people whose multiple myeloma had returned or stopped responding to treatment. The main goals were to find the highest safe dose and to get a first look at whether the treatments help control the cancer. The trial enrolled 30 adults and was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.